Atg14 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| ATG14 (BARKOR) | |
|---|---|
| Gene | ATG14 |
| UniProt ID | Q9Y4P8 |
| Molecular Weight | 57 kDa |
| Subcellular Localization | Autophagosome formation sites, ER |
| Protein Family | Autophagy-related proteins |
| Aliases | BARKOR, ATG14L, KIAA0831 |
| Protein Class | Phosphoinositide-binding protein |
ATG14 (BARKOR) is an essential autophagy protein that plays a critical role in autophagosome formation. Originally identified as a Beclin 1-interacting protein, ATG14 (also known as BARKOR) specifically targets the class III phosphoinositide 3-kinase (PI3K-III) complex to the sites of autophagosome biogenesis[1]. This function makes ATG14 a master regulator of autophagy initiation, distinguishing it from other Beclin 1-binding proteins that regulate autophagy in different contexts.
ATG14 contains several distinct structural domains that mediate its function:
The N-terminal BARKOR bundle domain (BBD) is required for homodimerization and for binding to the PI3K-III complex (containing VPS34, VPS15, and Beclin 1). This domain forms a parallel coiled-coil structure that facilitates protein-protein interactions[2].
The central claw domain is responsible for membrane association. This domain binds to phosphatidylinositol 3-phosphate (PI3P)-enriched membranes, particularly at the ER-mitochondria contact sites and omegasomes.
The C-terminal LIR domain mediates binding to LC3/GABARAP family proteins on the expanding autophagosome membrane. This interaction is crucial for selective autophagy and for the recruitment of autophagy cargo receptors.
Key residues involved in:
ATG14 is a master regulator of autophagy initiation through its actions at multiple stages:
During autophagy induction, ATG14 translocates to the ER and other membrane sources where it recruits and activates the PI3K-III complex. This complex generates phosphatidylinositol 3-phosphate (PI3P) on membrane surfaces, which serves as a platform for recruiting additional autophagy proteins[3].
ATG14 is essential for the formation of omegasomes—ER subdomain structures that serve as cradles for autophagosome biogenesis. These structures are marked by ZFYVE1 (DFCP1) and are the sites where the isolation membrane (phagophore) initially forms.
Through its LIR domain, ATG14 facilitates the recruitment of cargo receptors such as p62/SQSTM1, NBR1, and OPTN to the autophagosome. This enables selective degradation of protein aggregates, damaged mitochondria, and intracellular pathogens.
Recent structural studies have revealed that ATG14 functions as a membrane tether, bringing together different membrane sources to facilitate autophagosome expansion[4].
In AD, autophagy is significantly impaired, contributing to the accumulation of amyloid-beta plaques and tau tangles[5]:
Recent research has demonstrated that ATG14 levels correlate with cognitive function in AD patients, making it both a biomarker and therapeutic target[7].
PD is characterized by the accumulation of α-synuclein aggregates and mitochondrial dysfunction[8][9]:
ALS features accumulation of protein aggregates and mitochondrial dysfunction[10]:
HD is caused by mutant huntingtin (mHTT) protein aggregation:
The class III phosphoinositide 3-kinase (PI3K-III) complex is the核心 engine of autophagosome formation, with ATG14 serving as the targeting and regulatory subunit[11]:
| Component | Function | ATG14 Interaction |
|---|---|---|
| VPS34 | Catalytic subunit, produces PI3P | Direct binding via BBD |
| VPS15 (PIK3R4) | Regulatory subunit, scaffolding | ATG14 recruitment |
| BECN1 (Beclin 1) | Platform for regulatory interactions | ATG14 dimerization domain |
| ATG14 | Targeting subunit, regulatory | Central component |
The ATG14-containing PI3K-III complex (also called PI3K-III complex I, distinguishing from the Rubicon-containing complex II) is specifically required for autophagosome formation at the ER membrane[12].
ATG14 function is tightly regulated by phosphorylation[13][14]:
| Kinase | Site | Effect | Relevance |
|---|---|---|---|
| ULK1 | Ser-29, Ser-291 | Activation | Nutrient sensing |
| AMPK | Thr-233 | Activation | Energy stress |
| mTORC1 | Ser-237 | Inhibition | Nutrient sufficiency |
| TBK1 | Ser-29 | Activation | Innate immunity |
| CK2 | Multiple | Stability | Constitutive |
The phosphorylation status of ATG14 modulates its subcellular localization, protein interactions, and autophagic activity. In neurodegeneration, aberrant phosphorylation contributes to autophagy impairment.
ATG14 orchestrates autophagosome formation through coordinated membrane recruitment[15]:
ATG14 interacts with multiple autophagy proteins:
Drugs that enhance ATG14 function represent a promising therapeutic strategy[6:1]:
| Compound | Mechanism | Development Stage |
|---|---|---|
| Small-molecule GEF activators | Enhance ATG14-PI3K-III binding | Preclinical |
| mTOR inhibitors | Relieve ATG14 inhibition | Approved (rapamycin, everolimus) |
| AMPK activators | Activate ATG14 through phosphorylation | Clinical trials |
| PI3K-III agonists | Direct complex activation | Preclinical |
| Autophagy inducers | Broader activation including ATG14 | Various stages |
Natural compounds with ATG14-enhancing activity include:
AAV-mediated ATG14 overexpression shows promise in preclinical models:
CRISPR-based approaches for:
Recombinant ATG14 protein delivery is in early research:
Rational combinations for enhanced efficacy:
| Combination | Rationale | Expected Benefit |
|---|---|---|
| ATG14 + beclin 1 | Parallel activation | Synergistic autophagy |
| ATG14 + p62 | Enhance selective autophagy | Better aggregate clearance |
| ATG14 + mTOR inhibitor | Multiple pathway activation | Robust induction |
| ATG14 + antioxidants | Address oxidative stress | Neuroprotection |
ATG14 represents a promising therapeutic target for neurodegenerative diseases[6:2]:
| Strategy | Approach | Development Stage | Current Status |
|---|---|---|---|
| Small molecule activators | Compounds that enhance ATG14-PI3K-III binding | Preclinical | Lead compounds identified |
| Autophagy enhancers | mTOR inhibitors, AMPK activators | Clinical trials | Rapamycin in trials |
| Gene therapy | AAV-mediated ATG14 overexpression | Research | Preclinical efficacy |
| Protein therapy | Recombinant ATG14 protein delivery | Early research | Delivery optimization |
| Combination therapy | Multi-target approaches | Preclinical | Synergistic effects shown |
| Trial | Compound | Target | Phase | Status |
|---|---|---|---|---|
| NCT04593966 | Rapamycin | mTOR/ATG14 | Phase 2 | Recruiting |
| NCT05327248 | Metformin | AMPK/ATG14 | Phase 3 | Active |
| NCT04863451 | Everolimus | mTOR | Phase 2 | Completed |
The study of Atg14 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Matsunaga K, et al. Two Beclin 1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stages. Nat Cell Biol. 2009. ↩︎
Diao J, et al. ATG14 promotes membrane tethering. Nature. 2015. ↩︎
Mercer TJ, et al. Phosphoinositide 3-phosphate clearance and autophagy. J Cell Biol. 2018. ↩︎
Ravikumar B, et al. Regulation of autophagy in neurodegenerative diseases. Nat Rev Neurol. 2022. ↩︎
Zhang X, et al. ATG14 deficiency exacerbates tau pathology in Alzheimer's disease. J Neurosci. 2023. ↩︎
Chen H, et al. Targeting ATG14 for neurodegenerative disease therapy. Pharmacol Res. 2024. ↩︎ ↩︎ ↩︎
Chen X, et al. ATG14 and lipid droplet autophagy in neurodegeneration. Mol Neurodegener. 2023. ↩︎
Park S, et al. Restoration of ATG14 ameliorates alpha-synuclein pathology. Brain. 2023. ↩︎
Liu Y, et al. ATG14-mediated mitophagy in Parkinson's disease models. Cell Mol Neurobiol. 2024. ↩︎
Xie Y, et al. ATG14 regulates neuronal viability through autophagy. Cell Death Dis. 2020. ↩︎
Itakura E, et al. The Atg14 complex couples PI3P synthesis to autophagosome formation. Mol Biol Cell. 2008. ↩︎
Matsunaga K, et al. Autophagy requires endoplasmic reticulum exit sites. EMBO Rep. 2010. ↩︎
Menon MB, et al. ATG14 LKB1 regulates autophagy via AMPK-dependent phosphorylation. Nat Cell Biol. 2019. ↩︎
Wang L, et al. Phosphorylation status of ATG14 modulates autophagy flux. J Biol Chem. 2024. ↩︎
Yamamoto H, et al. Autophagosome formation in relation to the ER membrane. Nat Cell Biol. 2012. ↩︎